In a recent study published in Nanomedicine: Nanotechnology, Biology and Medicine, researchers evaluated the biodistribution of cannabidiol (CBD) emulsion and nanoparticles in the central nervous ...

A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection ...

THE neurologic manifestations of Central-nervous-system involvement in acute leukemia have been very well described. 1–7 Although involvement of the brain is not rare 7,8 greater emphasis has been ...

A 49 year old woman was diagnosed with Philadelphia negative B-acute lymphoblastic leukemia (B-ALL) and subsequently started on induction chemotherapy with systemic cyclophosphamide, doxorubicin, ...

Gene delivery into the spinal cord provides a potential approach to the treatment of spinal cord traumatic injury, amyotrophic lateral sclerosis, and spinal muscular atrophy. These disorders progress ...

Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04–03) No significant financial relationships to disclose ...

Credit: FDA. The FDA has received reports of tranexamic acid injection being erroneously administered intrathecally in the perioperative setting instead of the intended intrathecal anesthetic (eg, ...

Novartis has reported phase 1/2 trial results with its intrathecal formulation of gene therapy Zolgensma, placed under a clinical hold by the FDA last year, backing up its safety and efficacy.

January 29, 2009 (Honolulu, Hawaii) — Intrathecal therapies can relieve pain and improve long-term function, report specialists, but there are risks that should be taken into consideration. Speakers ...

high-frequency spinal cord stimulation controller Intrathecal drug delivery systems and spinal cord stimulation have shown promise for the treatment of cancer pain in initial studies. Cancer-related ...

The FDA has relaxed a clinical hold on clinical trials of Novartis' intrathecal formulation of spinal muscular atrophy (SMA) gene therapy Zolgensma, allowing a new phase 3 trial to get underway.